“…Considering the clinical (i.e., age, general clinical status, quality of life, frailty, comorbidities, other valves diseases, surgery impediments) and anatomical (i.e., femoral access status, aortic root morphology, size of aortic annulus, aortic valve morphology, concomitant coronary artery disease, coronary ostia origins, concomitant aortopathy) variables to be assessed in selecting the treatment for aortic stenosis, several HT members from different specialties (clinical cardiologist, cardiac imaging specialist, cardiac anaesthesiologist, and other medical specialists) continue to play a key role in this novel decision-making process. While the composition of the HT for aortic stenosis remains substantially unchanged, for the treatment of MR it becomes crucial to include the active participation of heart failure and mitral imaging specialists 4 . Indeed, evidence derived from randomised trials has shown that for functional MR the MitraClip device offers additional clinical benefits to optimal medical therapy in selected symptomatic patients with the strict echocardiographic criteria adopted in the COAPT trial 2 .…”